Alhambra Investment Management LLC Has $402,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Alhambra Investment Management LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,398 shares of the biopharmaceutical company’s stock after selling 531 shares during the period. Alhambra Investment Management LLC’s holdings in Halozyme Therapeutics were worth $402,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in HALO. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $49,000. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth $65,000. Finally, Park Place Capital Corp increased its holdings in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,209 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $54.80 on Friday. The stock has a market capitalization of $6.97 billion, a P/E ratio of 18.15, a price-to-earnings-growth ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The firm has a 50 day moving average of $49.62 and a 200-day moving average of $54.09. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on HALO shares. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright raised their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.